Starsource Multitrade

Starsource Multitrade P/B

The P/B (Price-to-Book Ratio) of Starsource Multitrade (506365.BO) as of Oct 27, 2026 is 13.16. In the previous year, P/B (Price-to-Book Ratio) was 1.29 — a change of 919.24% (higher).

P/B

13.16

YoY

919.24%

Last updated:

P/B (Price-to-Book Ratio) of Starsource Multitrade is 2026 13.16 . P/B (Price-to-Book Ratio) of Starsource Multitrade was 2025 1.29 . It decreases by 919.24% higher compared to the previous year.

The Starsource Multitrade P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2019
1.64 INR
Jan 1, 2020
1.58 INR
Jan 1, 2021
1.54 INR
Jan 1, 2022
1.47 INR
Jan 1, 2023
1.46 INR
Jan 1, 2024
1.33 INR
Jan 1, 2025
1.29 INR
Jan 1, 2026
13.16 INR
The Starsource Multitrade P/B history
YEARP/BYoY
13.16+919.24%
1.29-2.60%
1.33-9.38%
1.46-0.41%
1.47-4.85%
1.54-2.27%
1.58-3.86%
1.64-2.00%
1.68-0.99%
1.69-63.35%
4.62+39.44%
3.31-5.29%
3.50—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Starsource Multitrade Stock analysis

What does Starsource Multitrade do? Starsource Multitrade Ltd focuses on acquiring power and chemicals businesses, having transitioned from its former role as a pharmaceutical company. The company is exploring new business opportunities in the power and chemicals sectors, aiming to expand its portfolio through strategic acquisitions. Chemo Pharma Laboratories Ltd, which was formerly a pharmaceutical company, is now part of this strategic shift, though it has no current operations. The firm targets opportunities in power and chemicals to build its business model. The company's primary revenue stream comes from acquiring and developing power and chemicals businesses, with Chemo Pharma Laboratories Ltd serving as a former entity that has shifted focus. It does not currently operate any pharmaceutical business, instead concentrating on power and chemicals acquisitions. The business model relies on identifying and integrating new acquisitions in the power and chemicals sectors to generate revenue. Starsource Multitrade Ltd is actively seeking to acquire businesses in the power and chemicals sectors, having moved away from its pharmaceutical roots. The firm has no current operations, indicating a focus on future acquisitions rather than existing business activities. Chemo Pharma Laboratories Ltd, once a pharmaceutical company, is now part of the company's strategic repositioning towards power and chemicals. Starsource Multitrade is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Starsource Multitrade stock

P/B (Price-to-Book Ratio) of Starsource Multitrade is 13.16 in 2026.

P/B (Price-to-Book Ratio) of Starsource Multitrade changed from 1.29 to 13.16, representing a 919.24% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Starsource Multitrade since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Starsource Multitrade with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Starsource Multitrade

All Key Metrics — Starsource Multitrade